These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 35220871)

  • 1. Osilodrostat oral tablets for adults with Cushing's disease.
    Martino M; Aboud N; Lucchetti B; Salvio G; Arnaldi G
    Expert Rev Endocrinol Metab; 2022 Mar; 17(2):99-109. PubMed ID: 35220871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osilodrostat for the treatment of Cushing's disease.
    Rasool S; Skinner BW
    Expert Opin Pharmacother; 2021 Jun; 22(9):1099-1106. PubMed ID: 33703978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Utility of Osilodrostat in Cushing's Disease: Review of Currently Available Literature.
    Perosevic M; Tritos NA
    Drug Des Devel Ther; 2023; 17():1303-1312. PubMed ID: 37143705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Cushing's syndrome with osilodrostat: practical applications of recent studies with case examples.
    Fleseriu M; Biller BMK
    Pituitary; 2022 Dec; 25(6):795-809. PubMed ID: 36002784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase.
    Pivonello R; Fleseriu M; Newell-Price J; Bertagna X; Findling J; Shimatsu A; Gu F; Auchus R; Leelawattana R; Lee EJ; Kim JH; Lacroix A; Laplanche A; O'Connell P; Tauchmanova L; Pedroncelli AM; Biller BMK;
    Lancet Diabetes Endocrinol; 2020 Sep; 8(9):748-761. PubMed ID: 32730798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicenter, phase 2 study to evaluate the efficacy and safety of osilodrostat, a new 11β-hydroxylase inhibitor, in Japanese patients with endogenous Cushing's syndrome other than Cushing's disease.
    Tanaka T; Satoh F; Ujihara M; Midorikawa S; Kaneko T; Takeda T; Suzuki A; Sato M; Shimatsu A
    Endocr J; 2020 Aug; 67(8):841-852. PubMed ID: 32378529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osilodrostat for Cushing Disease and Its Role in Pediatrics.
    Groselj U; Sikonja J; Battelino T
    Horm Res Paediatr; 2023; 96(6):573-580. PubMed ID: 35045421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Updates in adrenal steroidogenesis inhibitors for Cushing's syndrome - A practical guide.
    Varlamov EV; Han AJ; Fleseriu M
    Best Pract Res Clin Endocrinol Metab; 2021 Jan; 35(1):101490. PubMed ID: 33707082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolonged adrenal insufficiency following discontinuation of osilodrostat treatment for intense hypercortisolism.
    Ferriere A; Salenave S; Puerto M; Young J; Tabarin A
    Eur J Endocrinol; 2024 Jan; 190(1):L1-L3. PubMed ID: 38123490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osilodrostat: A Review of Recent Clinical Studies and Practical Recommendations for its Use in the Treatment of Cushing Disease.
    Yuen KCJ
    Endocr Pract; 2021 Sep; 27(9):956-965. PubMed ID: 34389514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osilodrostat: A Novel Steroidogenesis Inhibitor to Treat Cushing's Disease.
    Dougherty JA; Desai DS; Herrera JB
    Ann Pharmacother; 2021 Aug; 55(8):1050-1060. PubMed ID: 33143437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osilodrostat - an emerging drug for the medical management of Cushing's disease.
    Witek P; Mehlich A; Stasiewicz A; Jawiarczyk-Przybyłowska A; Bolanowski M
    Endokrynol Pol; 2022; 73(2):371-374. PubMed ID: 35381096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing's disease.
    Fleseriu M; Pivonello R; Young J; Hamrahian AH; Molitch ME; Shimizu C; Tanaka T; Shimatsu A; White T; Hilliard A; Tian C; Sauter N; Biller BM; Bertagna X
    Pituitary; 2016 Apr; 19(2):138-48. PubMed ID: 26542280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osilodrostat: 11β-hydroxylase inhibitor for treatment of Cushing's disease.
    Paton DP
    Drugs Today (Barc); 2020 Oct; 56(10):643-654. PubMed ID: 33185629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Corticotroph tumor progression during long-term therapy with osilodrostat in a patient with persistent Cushing's disease.
    Fontaine-Sylvestre C; Létourneau-Guillon L; Moumdjian RA; Berthelet F; Lacroix A
    Pituitary; 2021 Apr; 24(2):207-215. PubMed ID: 33074401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement in clinical features of hypercortisolism during osilodrostat treatment: findings from the Phase III LINC 3 trial in Cushing's disease.
    Pivonello R; Fleseriu M; Newell-Price J; Shimatsu A; Feelders RA; Kadioglu P; Tabarin A; Brue TC; Geer EB; Piacentini A; Pedroncelli AM; Biller BMK
    J Endocrinol Invest; 2024 Oct; 47(10):2437-2448. PubMed ID: 38696122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metyrapone Versus Osilodrostat in the Short-Term Therapy of Endogenous Cushing's Syndrome: Results From a Single Center Cohort Study.
    Detomas M; Altieri B; Deutschbein T; Fassnacht M; Dischinger U
    Front Endocrinol (Lausanne); 2022; 13():903545. PubMed ID: 35769081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osilodrostat Is a Potential Novel Steroidogenesis Inhibitor for the Treatment of Cushing Syndrome: An In Vitro Study.
    Creemers SG; Feelders RA; de Jong FH; Franssen GJH; de Rijke YB; van Koetsveld PM; Hofland LJ
    J Clin Endocrinol Metab; 2019 Aug; 104(8):3437-3449. PubMed ID: 31127821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cushing's disease: adrenal steroidogenesis inhibitors.
    Pivonello R; Simeoli C; Di Paola N; Colao A
    Pituitary; 2022 Oct; 25(5):726-732. PubMed ID: 36036308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcomes of osilodrostat in Cushing's disease: LINC 3 study extension.
    Fleseriu M; Newell-Price J; Pivonello R; Shimatsu A; Auchus RJ; Scaroni C; Belaya Z; Feelders RA; Vila G; Houde G; Walia R; Izquierdo M; Roughton M; Pedroncelli AM; Biller BMK
    Eur J Endocrinol; 2022 Oct; 187(4):531-541. PubMed ID: 35980235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.